print_label | resize_label

A TREATMENT FOR ADULTS WITH TYPE 2 DIABETES MELLITUS, IN ADDITION TO DIET AND EXERCISE

DEMONSTRATED REDUCTIONS IN A1C LEVELS WITH ONGLYZA

CLINICAL TRIALS

ONGLYZA AS ADD-ON THERAPY

To metformin IR

ONGLYZA led to significant reductions in A1C levels when added to metformin therapy in patients with inadequately controlled type 2 diabetes mellitus with metformin alone1,2

INITIAL COMBINATION THERAPY WITH ONGLYZA

5 mg + metformin IR

ONGLYZA given in combination with metformin as initial therapy improved glycemic control in patients with type 2 diabetes mellitus compared with ONGLYZA or metformin as monotherapy1,3 

 

ONGLYZA HEAD-TO-HEAD VS A SULFONYLUREA

5 mg vs up-titrated glipizide as add-on to metformin IR

ONGLYZA demonstrated reductions in A1C levels comparable to glipizide with lower rates of hypoglycemia1,4

 

ONGLYZA IN RENALLY IMPAIRED PATIENTS

2.5 mg vs placebo

ONGLYZA demonstrated significant reductions in A1C levels with similar rates of hypoglycemia, in renally impaired patients1,5